Phase I clinical trial of a single-dose and two weekly schedules of ICRF-159 (NSC-129943).
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D001792:Blood Platelets; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D000970:Antineoplastic Agents